We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical

274 hedge funds and large institutions have $3.63B invested in Ultragenyx Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 117 increasing their positions, 80 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 36 (+3)

52% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $15M

46% more repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 80

18% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 40

2% more funds holding

Funds holding: 269274 (+5)

0.33% more ownership

Funds ownership: 97.06%97.4% (+0.33%)

3% less capital invested

Capital invested by funds: $3.73B → $3.63B (-$103M)

Holders
274
Holders Change
+5
Holders Change %
+1.86%
% of All Funds
3.96%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
47
Increased
117
Reduced
80
Closed
40
Calls
$22.7M
Puts
$15M
Net Calls
+$7.77M
Net Calls Change
-$6.85M
Name Holding Trade Value Shares
Change
Change in
Stake
Legal & General Group
101
Legal & General Group
United Kingdom
$3.51M +$64.3K +1,506 +2%
California State Teachers Retirement System (CalSTRS)
102
California State Teachers Retirement System (CalSTRS)
California
$3.02M -$41.5K -972 -1%
HWAM
103
Hennion & Walsh Asset Management
New Jersey
$3.01M +$1.01M +23,752 +48%
Janus Henderson Group
104
Janus Henderson Group
United Kingdom
$2.95M +$1.69M +39,592 +123%
State of Wisconsin Investment Board
105
State of Wisconsin Investment Board
Wisconsin
$2.9M +$843K +19,746 +39%
ACM
106
Altium Capital Management
New York
$2.88M +$2.99M +70,000 New
Alyeska Investment Group
107
Alyeska Investment Group
Illinois
$2.88M +$2.99M +70,000 New
BNP Paribas Financial Markets
108
BNP Paribas Financial Markets
France
$2.77M +$2.03M +47,579 +239%
Barclays
109
Barclays
United Kingdom
$2.59M -$2.39M -55,860 -47%
DekaBank Deutsche Girozentrale
110
DekaBank Deutsche Girozentrale
Germany
$2.36M
GCM
111
Graham Capital Management
Connecticut
$2.28M +$493K +11,538 +26%
New York State Common Retirement Fund
112
New York State Common Retirement Fund
New York
$2.25M -$321K -7,524 -12%
PP
113
PDT Partners
New York
$2.16M +$43 +1 +0%
AG
114
Algert Global
California
$2.07M +$1.1M +25,752 +105%
WAM
115
Weiss Asset Management
Massachusetts
$2.06M +$2.13M +50,000 New
NIM
116
NEOS Investment Management
Connecticut
$2.01M +$728K +17,058 +54%
State of New Jersey Common Pension Fund D
117
State of New Jersey Common Pension Fund D
New Jersey
$2M -$287K -6,721 -12%
GC
118
Guggenheim Capital
Illinois
$1.67M +$201K +4,701 +13%
NIG
119
NFJ Investment Group
Texas
$1.64M -$174K -4,069 -9%
Treasurer of the State of North Carolina
120
Treasurer of the State of North Carolina
North Carolina
$1.56M +$123K +2,878 +8%
Nordea Investment Management
121
Nordea Investment Management
Sweden
$1.55M -$309K -7,230 -16%
UOC
122
UBS O'Connor
Illinois
$1.44M -$319K -7,478 -18%
Tudor Investment Corp
123
Tudor Investment Corp
Connecticut
$1.42M +$1.48M +34,563 New
CCIA
124
Campbell & Co Investment Adviser
Maryland
$1.39M +$1.45M +33,868 New
Ohio Public Employees Retirement System (OPERS)
125
Ohio Public Employees Retirement System (OPERS)
Ohio
$1.37M +$137K +3,198 +11%

RARE Hedge Fund Activity: Q2 2024 in Review

274 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2024, worth a combined $3.63B — down 2.8% from $3.73B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new RARE positions and 40 closed out — a net gain of 7 holders — while 117 added to existing stakes and 80 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $72.2M. The largest seller was RTW Investments, cutting an estimated $163M.

  • 274 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2024, up from 269 in Q1 2024.
  • Funds reported $3.63B of Ultragenyx Pharmaceutical stock for Q2 2024, down 2.8% quarter-over-quarter.
  • 47 funds opened new Ultragenyx Pharmaceutical positions in Q2 2024 and 40 closed out, a net change of +7 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q2 2024 was Vestal Point Capital, an estimated $72.2M added.
  • The largest Ultragenyx Pharmaceutical seller in Q2 2024 was RTW Investments, an estimated $163M sold.

Based on aggregated 13F filings for Q2 2024.